The combination of CJC-1295 (a GHRH analog) and Ipamorelin (a selective growth-hormone-releasing peptide, GHRP) is the most extensively studied dual-mechanism approach to investigating pulsatile growth hormone (GH) secretion in research models. Unlike single-compound GH research, the combined stack engages two distinct receptor systems — GHRH-R and GHS-R1a — producing additive GH release that more closely approximates the natural pulsatile pattern observed in healthy adult physiology.
This guide covers the mechanistic basis for combining these compounds, the practical distinction between CJC-1295 with and without DAC, ipamorelin's selectivity profile vs other GHRPs, and the documentation standards required for credible research use.
The Two-Receptor Rationale
GH secretion is governed by two physiological signals at the somatotroph cell of the anterior pituitary:
- GHRH (growth-hormone-releasing hormone), signalling through the GHRH-R receptor, drives GH transcription and amplifies pulse magnitude.
- Ghrelin, signalling through the GHS-R1a receptor, drives GH pulse initiation and synergises with GHRH to amplify amplitude.
The two signals are not redundant. GHRH alone produces modest GH release; ghrelin alone produces modest GH release; the two together produce a release substantially greater than the sum of either alone. This synergy is the experimental rationale for combining a GHRH analog with a GHRP in research protocols.
CJC-1295 is a tetrasubstituted GHRH analog modified at positions 2, 8, 15, and 27 to resist DPP-IV cleavage and oxidation. Ipamorelin is a synthetic pentapeptide GHRP that activates GHS-R1a with high selectivity, avoiding the cortisol/prolactin elevation seen with earlier GHRPs.
CJC-1295: With DAC vs Without DAC
This is the most important practical distinction in CJC-1295 research and the one most commonly misunderstood.
CJC-1295 without DAC (also called Modified GRF 1-29, mod GRF 1-29)
This is the bare GHRH analog with the four DPP-IV–resistant substitutions but no albumin-binding tail. Half-life is approximately 30 minutes, comparable to native GHRH. It produces clean, short-duration GH pulses matching native pulsatile physiology. Most research stacking protocols use this form.
- CAS: 863288-34-0
- Half-life: ~30 minutes
- Pulse profile: Short, physiological
CJC-1295 with DAC (Drug Affinity Complex)
The same GHRH analog with a maleimidopropionyl (MPA) linker added at the C-terminus. The MPA group binds covalently to serum albumin, extending half-life to 6–8 days. This sustained-release form produces continuous low-level GH elevation rather than physiological pulsing, which is mechanistically distinct from the without-DAC form.
- Half-life: 6–8 days
- Pulse profile: Sustained elevation, non-physiological
For research models attempting to replicate natural pulsatile GH dynamics, CJC-1295 without DAC is the appropriate tool compound. The DAC form is studied in different contexts — typically chronic continuous-release pharmacology — and is not interchangeable with the without-DAC version despite both being labelled "CJC-1295".
Ipamorelin: Selectivity Profile
Ipamorelin (CAS 170851-70-4, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) is the most selective GHRP characterised in the published literature. Compared to first-generation GHRPs like GHRP-2 and GHRP-6, ipamorelin shows minimal cross-activation of:
- CRH/cortisol axis — clinically meaningful elevations seen with GHRP-2/6 are absent
- Prolactin — minimal release vs significant elevation with GHRP-6
- Appetite signalling — ipamorelin lacks the orexigenic effects of GHRP-6
This selectivity is why ipamorelin became the canonical GHRP for research where the experimental endpoint is GH release specifically, rather than a generalised neuroendocrine response.
Combined Stack: Mechanistic Synergy
| Aspect | CJC-1295 (no DAC) | Ipamorelin | Combined |
|---|---|---|---|
| Receptor | GHRH-R | GHS-R1a | Both |
| Mechanism | GHRH agonism | Ghrelin mimetic | Dual |
| GH amplitude | Moderate | Moderate | Synergistic (greater than sum) |
| GH pulse pattern | Amplification | Initiation | Physiological mimic |
| Cortisol | None | Minimal | Minimal |
| Prolactin | None | Minimal | Minimal |
Research Design Considerations
Timing
Native GH pulses occur predominantly during slow-wave sleep with a secondary daytime pulse around 4–6 hours after the prior pulse. Research stacks typically administer both compounds simultaneously to model a single combined pulse, with sampling at 15-minute intervals over a 2-hour window for capture of the GH peak (typically observed at 20–40 minutes post-administration).
Dose ratios
The published literature on the combined approach typically uses CJC-1295 (no DAC) and ipamorelin at equal mass doses, though receptor pharmacology arguments exist for asymmetric ratios. Researchers should consult primary sources for their specific experimental model and not assume manufacturer dosing guides reflect peer-reviewed protocols.
Endpoint measurement
GH assays vary in sensitivity. Modern immunoassays (chemiluminescent, ECLIA) capture pulsatile peaks reliably; older RIA methods may miss short-duration peaks. IGF-1 is a downstream marker but requires 24–48 hours to reflect upstream GH changes and is therefore not suitable for single-pulse research.
For accurate replication of published GHRH/GHRP synergy studies, both compounds must meet ≥99% HPLC purity. Sub-threshold ipamorelin may contain D-amino-acid epimers that bind GHS-R1a with altered affinity, confounding amplitude measurements.
Purity and COA Standards
Both compounds are SPPS products with well-characterised impurity profiles:
CJC-1295 (no DAC)
- ≥99% HPLC purity, UV 220 nm
- Mass spectrometry at expected molecular ion (m/z 3367.9, [M+H]+)
- Quantification of deletion sequences at positions 2, 8, 15, 27 (D-Ala, Gln, Ala, Leu substitutions)
Ipamorelin
- ≥99% HPLC purity, UV 220 nm
- Mass spectrometry confirmation at m/z 712.4 [M+H]+
- D-amino acid epimer quantification (D-2-Nal, D-Phe positions)
- C-terminal amide intact (not free acid)
A complete COA documents both compounds individually, not generic certifications. Batch-specific HPLC chromatograms and mass spectra are the minimum acceptable documentation.
CJC-1295 + Ipamorelin Research Blend
5mg/5mg lyophilised · ≥99% HPLC-MS · Batch COA · EU delivery
View Research Blend →Summary
CJC-1295 (without DAC) and ipamorelin together engage GHRH-R and GHS-R1a respectively, producing synergistic GH release that approximates physiological pulsing. The without-DAC form of CJC-1295 is the appropriate tool compound for pulsatile research; the with-DAC form is mechanistically distinct. Ipamorelin's selectivity for GHS-R1a — sparing cortisol, prolactin, and appetite axes — makes it the canonical GHRP for endpoint-specific GH research. Both compounds require ≥99% HPLC-MS purity with batch-specific COA to support credible experimental conclusions.